Loading
A phase 3 trial of Mosunetuzumab, Lenalidomide, Rituximab in follicular lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma is a phase 3 interventional study registered as NCT04712097 by Hoffmann-La Roche, with 478 participants enrolled, started 2021-10-27 and due to reach its primary completion in 2026-06-03. Interventions recorded: Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab. Conditions listed: Relapsed or Refractory Follicular Lymphoma. No results are recorded here; the registry entry is the source.
Shares Mosunetuzumab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Roche / Genentech.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.